Publications

  1. Maly CJ, Cumsky HJL, Costello CM, Schmidt JE, Butterfield RJ, Zhang N, DiCaudo DJ, Nelson SA, Smith ML, Ochoa SA, Baum CL, Nagel TH, Pittelkow MR, Sekulic A, Mangold AR. Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2019 Aug 19 [Epub ahead of print]
    View PubMed
  2. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, ERIVANCE BCC Investigators. Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2019 Apr 18; 19 (1):366
    View PubMed
  3. Cumsky HJL, Costello CM, Zhang N, Butterfield R, Buras MR, Schmidt JE, Drenner K, Nelson SA, Ochoa SA, Baum CL, Pittelkow MR, DiCaudo DJ, Sekulic A, Mangold AR. The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2019 Mar; 80 (3):626-632.e1 Epub 2018 Oct 22
    View PubMed
  4. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 Jan 1; 125 (1):18-44 Epub 2018 Oct 03
    View PubMed
  5. Mangold AR, Cumsky HJL, Costello CM, Xie DY, Buras MR, Nelson SA, DiCaudo DJ, Sekulic A, Pittelkow MR. Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case-control study. J Am Acad Dermatol. 2018 Nov; 79 (5):913-920.e1 Epub 2018 June 18
    View PubMed
  6. Hendricks WPD, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery NS, Washington M, Aldrich J, Neff MW, Huentelman MJ, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent JM. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet. 2018 Sep; 14 (9):e1007589 Epub 2018 Sept 06
    View PubMed
  7. Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018 May 9; 8 (1):7375 Epub 2018 May 09
    View PubMed
  8. Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clin Cancer Res. 2018 Apr 15; 24 (8):1932-1943 Epub 2018 Feb 09
    View PubMed
  9. Kim JYS, Baum C, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P, Work Group//Invited Reviewers, Miller A, Sekulic A. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018 Mar; 78 (3):540-559 Epub 2018 Jan 10
    View PubMed
  10. Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P, Work Group//Invited Reviewers. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018 Mar; 78 (3):560-578 Epub 2018 Jan 10
    View PubMed
  11. Patel AB, Mangold AR, Costello CM, Nagel TH, Smith ML, Hayden RE, Sekulic A. Frequent loss of inositol polyphosphate-5-phosphatase in oropharyngeal squamous cell carcinoma. J Eur Acad Dermatol Venereol 2018 Jan; 32 (1):e36-e37 Epub 2017 Aug 02
    View PubMed
  12. Yang YW, Macdonald JB, Nelson SA, Sekulic A. Treatment of vismodegib-associated muscle cramps with cyclobenzaprine: A retrospective review. J Am Acad Dermatol 2017 Dec; 77 (6):1170-1172
    View PubMed
  13. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16; 17 (1):332
    View PubMed
  14. Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses. Oncotarget. 2017 Apr 25; 8: (17)27786-27799.
    View PubMed
  15. Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res. 2017 Apr; 27 (4):524-532
    View PubMed
  16. Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged >/=65 years with advanced basal cell carcinoma. Oncotarget. 2016 Nov 15; 7 (46):76118-76124
    View PubMed
  17. Kang HJ, Cui Y, Yin H, Scheid A, Hendricks WPD, Schmidt J, Sekulic A, Kong D, Trent JM, Gokhale V, Mao H, Hurley LH. A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters. J Am Chem Soc. 2016 Oct 19; 138 (41):13673-13692 Epub 2016 Oct 05
    View PubMed
  18. Lacouture ME, Dreno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist. 2016 Oct; 21 (10):1218-1229 Epub 2016 Aug 10
    View PubMed
  19. Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 Sep 1; 11 (1):120 Epub 2016 Sept 01
    View PubMed
  20. Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA. Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma. Dermatol Surg. 2016 May; 42 (5):646-52
    View PubMed
  21. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 May; 14: (5)574-97.
    View PubMed
  22. Mangold AR, DiCaudo DJ, Blair JE, Sekulic A. Chronic interstitial granulomatous dermatitis in coccidioidomycosis. Br J Dermatol. 2016 Apr; 174: (4)881-884.
    View PubMed
  23. Sekulic A, Von Hoff D. Hedgehog Pathway Inhibition. Cell. 2016 Feb 25; 164: (5)831.
    View PubMed
  24. LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Mol Cancer Ther. 2015 Aug; 14 (8):1962-71 Epub 2015 June 10
    View PubMed
  25. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Dirix L, Hou J, Yue H, Hauschild A. A pivotal ERIVANCE BCC study: A 12-month update of efficacy and safety of Vismodegib in advanced basal cell carcinoma (in press). J Amer Acad Dermatol. 2015 Jul.
  26. Sekulic A, Tang J, Rogers G, Olenicki T, Lacouture M, Kudchadkar R, Yoo S, Guillen J, Mun Y, Chen D, Flick D. RegiSONIC: a prospective observational study of treatment in advanced basal cell carcinoma (aBCC) and basal cell carcinoma nevus syndrome (BCCNS) patient (in press). J Amer Acad Dermatol. 2015 Jul.
  27. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A, ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72 (6):1021-6.e8
    View PubMed
  28. Sekulic A, Liang WS, Tembe W, Izatt T, Kruglyak S, Kiefer JA, Cuyugan L, Zismann V, Legendre C, Pittelkow MR, Gohmann JJ, De Castro FR, Trent J, Carpten J, Craig DW, McDaniel TK. Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion. Mol Genet Genomic Med. 2015 Mar; 3 (2):130-6 Epub 2014 Nov 27
    View PubMed
  29. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015 Feb; 72(2):221-36; quiz 237-8.
    View PubMed
  30. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015 Feb; 72 (2):203-18; quiz 219-20
    View PubMed
  31. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014 May; 46 (5):427-9 Epub 2014 Mar 23
    View PubMed
  32. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, Hou J, Wang L, Yue H, Hauschild A. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014 Mar; 50(4):774-83. Epub 2014 Jan 09.
    View PubMed
  33. Ramos P, Karnezis AN, Hendricks WP, Wang Y, Tembe W, Zismann VL, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, Huntsman DG, Trent JM. Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Rare Dis. 2014; 2 (1):e967148 Epub 2014 Nov 03
    View PubMed
  34. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013 May; 25(3):218-23.
    View PubMed
  35. Barrett MT, Lenkiewicz E, Evers L, Holley T, Ruiz C, Bubendorf L, Sekulic A, Ramanathan RK, Von Hoff DD. Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol. 2013; 4:2 Epub 2013 Jan 28
    View PubMed
  36. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7; 366 (23):2171-9
    View PubMed
  37. Egnatios GL, Dueck AC, Macdonald JB, Laman SD, Warschaw KE, DiCaudo DJ, Nemeth SA, Sekulic A, Gray RJ, Wasif N, Pockaj BA. The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma. Am J Surg. 2011 Dec; 202(6):771-7; discussion 777-8. Epub 2011 Oct 13.
    View PubMed
  38. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011; 2:538-43 Epub 2011 Nov 01
    View PubMed
  39. Stucky CC, Gray RJ, Dueck AC, Wasif N, Laman SD, Sekulic A, Pockaj BA. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg. 2010 Dec; 200(6):770-4; discussion 774-5.
    View PubMed
  40. Sekulic A, Colgan MB, Davis MD, DiCaudo DJ, Pittelkow MR. Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol. 2010 Nov; 163(5):1095-8.
    View PubMed
  41. Sekulic A, Kim SY, Hostetter G, Savage S, Einspahr JG, Prasad A, Sagerman P, Curiel-Lewandrowski C, Krouse R, Bowden GT, Warneke J, Alberts DS, Pittelkow MR, DiCaudo D, Nickoloff BJ, Trent JM, Bittner M. Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma. Cancer Prev Res (Phila). 2010 Oct; 3 (10):1277-83 Epub 2010 Sept 28
    View PubMed
  42. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist. 2010; 15 (9):1016-22 Epub 2010 Aug 26
    View PubMed
  43. Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR, Melanoma Study. Metastatic malignant melanoma. G Ital Dermatol Venereol. 2009 Feb; 144(1):1-26.
    View PubMed
  44. Carpenter S, Pockaj B, Dueck A, Gray R, Kurtz D, Sekulic A, Casey W. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg. 2008 Dec; 196(6):834-42; discussion 842-3.
    View PubMed
  45. Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN, Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008 Jul; 83 (7):825-46
    View PubMed
  46. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000 Jul 1; 60 (13):3504-13
    View PubMed
  47. Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC Jr, Houghton PJ. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol. 1998 Nov; 54(5):815-24.
    View PubMed
  48. Kennedy AP, Sekulic A, Irvin BJ, Nilson AE, Dilworth SM, Abraham RT. Polyomavirus middle T antigen as a probe for T cell antigen receptor-coupled signaling pathways. J Biol Chem. 1998 May 8; 273 (19):11505-13
    View PubMed
  49. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC, Abraham RT. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 1997 Jul 4; 277(5322):99-101.
    View PubMed